Identified new technologies and negotiated terms for licensing, collaboration, and OEM agreements. • Obtained business approval for new technologies and academic/institutional collaborations • Negotiated terms for licensing, collaborations, and consultants.• Executed agreements for licenses to commercialize technologies.• Technology highlights includeo novel Stem Cell technology o cutting edge Neuroscience visualization technologyo mAb library for Systems Immunologyo Small Molecule regulators (inhibitors) for cell signaling, cancer, metabolism• Identified New Targets for in house product development• Developed web based competition analysis tool (CAT) that cross references targets with competition offerings using unique identifiers (eg. Uniprot, Gene Symbol, CAS)• Published two (2) peer reviewed papers related to kinome bioinformatics for drug discovery.

Established and managed bio- and cheminformatics capabilities within new R&D team responsible for identifying targets for reagent and assay development (3 Ph.D. and 1 Technician as direct reports).• Established workflow for target selection incorporating both open source and proprietary databases and pathway analysis tools.• Developed custom software solution for batch publication query, data analysis, and visualization (PubMed Plus).• Developed custom software solution for text mining of publications for novel small molecule inhibitors (PubMed Miner).• Established and launched corporate-wide human proteome database linking human protein targets with small molecules, pathways, diseases, NIH grant funding and relevant publications (Protein Warehouse).• Using new tools, introduced new antibodies and small molecule inhibitors as cutting edge research reagents.• Spearheaded and managed large kinome activity screen as part of cross divisional innovation project related to kinase bioinformatics. Bio- and cheminformatics analysis of large data set identified new targets based upon activity fingerprint.• Obtained corporate commitment for multi-site global R&D projects with budgets in excess of one million dollars.• Developed and managed multimillion dollar assay and reagent portfolio for drug development market with specific focus in the following product areas, toxicology, metabolism, biomarkers, stem cells.

Identified and negotiated terms for licensing, collaboration, and OEM agreements. Excelled in a fast-paced environment, working under strict deadlines. • Identified and negotiated terms for licensing, collaboration, and OEM .• Introduced 128 new products in the areas of cell signaling, toxicology, metabolism, and stem cells.• Product areas included Antibodies (poly and mono), Proteins/Enzymes, Immunoassays, Cell based assays.• Coordinated all supporting product data from partners and drove the generation of marketing material for all products above.• Identified and executed stem cell research collaborations related to small molecules with multiple academic and industry partners.• Successfully initiated and developed strategy for obtaining corporate financing of significant stem cell research collaboration with academic partner.

• Developed and launched commercial assays for monitoring important gene and cellular functions and pathways.• Developed and commercialized flow based assays for mitochondrial, cytochrome c, and apoptosis analysis.• Developed and commercialized eight (8) microwell non-radioactive kinase assays (K-LISA Activity Kits). apoptosis, Akt, mTOR, DNA damage, inflammation, cell cycle.• Developed biggest selling assay kit in EMD Bioscience history.• Developed and characterized 45 new antibodies for important pathway regulators.

• NIH NRSA Postdoctoral Training Award• Defined DNA replication origins and their regulation using a vertebrate cell free system.• Published three (3) papers in peer reviewed journals (Journal of Biochemistry, Molecular and Cellular Biology, Genes and Development).• Developed cell and cell-free assays for determination of cell cycle and DNA checkpoint activation.• Determined role of DNA methylation in the specification of DNA replication origins.• Developed chromatin immunoprecipitation (ChIP) assays for use in DNA replication origin identification.